TIME has published its World's Top HealthTech Companies of 2026, compiled with the data firm Statista. Neeuro is on the list.
We did not apply for it, and nobody told us in advance. We found out the way most people will — by reading the table.
I want to say thank you, and then be straight about what a listing like this does and does not tell you. Both parts matter.
TIME and Statista analysed thousands of health technology companies and published the 500 with the highest scores, drawn from 34 countries. The scoring rests on three pillars: financial performance at 50% of the weighting, assessed through metrics including revenue per employee and funding; reputation at 30%, measured by social listening across news coverage, blogs, forums and social media; and online engagement at 20%, measured by website traffic.
Each listed company is placed in one of six market segments, and given a performance label of Outstanding, Very High or High.
Neeuro is listed under Prevention — Statista's segment for digital applications that promote health and wellness, including behavioural change programmes and coaching solutions. That is a fair description of what we do, and we are glad to be read that way rather than as a medical device company, which we are not.
Our performance label is Outstanding, which the published methodology awards to companies in the top third of the 500 with at least two of the three pillar scores at 85% or above. Seventy-four of the 500 companies received it. Four of those are in Prevention: Neko Health in Sweden, Well and Wisdo Health in the United States, and us.
Five Singapore companies appear on the list. We are pleased to be among them, and to be in the company of teams like Respiree, BIMA, WhiteCoat and Homage, all of whom are doing serious work.
This is the part that would be easy to leave out, so let me put it plainly.
Two of the three pillars — reputation and online engagement, together 50% of the score — measure how visible a company is, not how well its products work. Visibility is worth something. It is not the same as efficacy, and we would not want anyone to read this listing as a clinical result. It isn't one.
The list also measures performance up to a point in time. It says nothing about whether we will still deserve it next year.
And it is a snapshot of a company, not of the people a company serves. The measures that actually matter to us are slower and less flattering to report: whether a child finishes a training programme, whether a clinician finds the data useful, whether a developer ships something they could not have shipped before.
If the listing reflects anything real, it reflects thirteen years of accumulated work — and very little of that work was done by one team in isolation.
Dry electrodes that hold a clean signal on a moving human head. Attention, relaxation and mental workload models trained until they generalised past the laboratory. A randomised controlled trial of 172 children, published in PLOS ONE. Applications — Cogo, Memorie, Galini, MindViewer — and the partners who built on them. Research carried out with A*STAR and Duke-NUS.
Each of those depended on people outside this company: the researchers who ran the trials, the clinicians and teachers who told us when something did not work in a real room with real children, the partners who bet on an unproven platform, and the families who gave us their time.
NeeuroOS Agent is the newest layer of that stack, not a departure from it. It can turn a plain-English description into a working brain-computer interface application only because the hardware, the models and the evidence were already there to point it at — and those were built slowly, by a lot of hands, over a long time.
The work this week is the same as the work last week: making it easier for the people who understand a problem to build the tool that addresses it, without first having to become EEG engineers. A line in a table does not move that along. It is, though, a decent moment to say thank you to everyone who has.
If you would like to see what the stack does, it is at www.neeuro.ai.
Alvin Chan, PhD
Co-Founder & CEO, Neeuro
The full list and TIME and Statista's methodology are published at time.com.
Neeuro products are not medical solutions and should not be used to diagnose or treat any medical condition. Individual results may vary.